Latest Conference Articles

The OncLive® Conference page includes a listing of all conferences covered by OncLive®, including the ASCO, ESMO, SITC, EHA, ASH, and SABCS annual meetings, as well as the Chemotherapy Foundation Symposium and Miami Breast Cancer Conference, among many others. Conference coverage incorporates articles and interviews in written and video format.

Recurrence-Free Interval Is Longer With Low ctDNA Levels at Baseline in TNBC

Recurrence-Free Interval Is Longer With Low ctDNA Levels at Baseline in TNBC

December 13th 2024

ctDNA was most frequently detected within 6 months post-treatment in patients with TNBC, aligning with the early recurrence pattern characteristic of the disease.

Breast Cancer | Image Credit: © Axel Kock – stock.adobe.com

Perioperative Atezolizumab Plus Chemo Does Not Improve EFS in TNBC

December 13th 2024

Treatment with atezolizumab and neoadjuvant chemotherapy followed by adjuvant atezolizumab did not improve EFS in triple-negative breast cancer.

Breast Cancer

T-DXd Preserves QOL, Neurological Function in HER2+ Metastatic Breast Cancer Irrespective of Brain Metastases

December 13th 2024

T-DXd displayed favorable HRQOL and neurological function results in HER2+ metastatic breast cancer regardless of the presence of brain metastases.

Breast cancer | Image Credit: © Sebastian Kaulitzki – stock.adobe.com

Neoadjuvant Niraparib Plus Dostarlimab Generates pCRs in BRCA+ ER+/HER2– Breast Cancer

December 13th 2024

Treatment with preoperative niraparib plus dostarlimab generated responses among patients with BRCA-mutant, ER-positive, HER2-negative breast cancer

Triple-Negative Breast Cancer | Image Credit: © Sebastian Kaulitzki – stock.adobe.com

Camrelizumab/Chemo Could Represent New Neoadjuvant Option in Early or Locally Advanced TNBC

December 13th 2024

Neoadjuvant camrelizumab paired with chemotherapy significantly improved pCR over chemotherapy alone in early or locally advanced TNBC.

ASH Annual meeting | Image Credit: © Tatiana Shepeleva – stock.adobe.com

100-mg Bezuclastinib Improves Symptoms, Biomarkers in Non-Advanced Systemic Mastocytosis

December 13th 2024

Treatment with a 100-mg dose of bezuclastinib had a favorable safety and tolerability profile in patients with non-advanced systemic mastocytosis.

Mariya Rozenblit, MD, assistant professor, medicine (medical oncology), Yale School of Medicine

Dr Rozenblit on Pembrolizumab Outcomes by TMB Status in HR+ Metastatic Breast Cancer

December 13th 2024

Mariya Rozenblit, MD, discusses how genomic alterations and TMB influence the efficacy of immune checkpoint inhibitors in HR+ metastatic breast cancer.

Maxwell Lloyd, MD, clinical fellow, medicine, Department of Medicine, Beth Israel Deaconess Medical Center

Dr Lloyd on the Effects of ESR1 Mutations on Elacestrant Outcomes in HR+ Advanced Breast Cancer

December 13th 2024

Maxwell Lloyd, MD, discusses a real-world study of elacestrant outcomes based on prior treatment and ESR1 mutation status in HR+ breast cancer.

Breast Cancer | Image Credit: © Axel Kock – stock.adobe.com

Palbociclib Plus Anti-HER2 and Endocrine Therapy Prolongs PFS in HR+/HER2+ Breast Cancer

December 12th 2024

Palbociclib plus anti-HER2 and endocrine therapy improved progression-free survival in hormone receptor–positive, HER2-positive metastatic breast cancer.

Breast Cancer | stock.adobe.com

Tamoxifen Reduces Ipsilateral Breast Recurrence in Good-Risk Ductal CIS

December 12th 2024

Tamoxifen reduced the risk of invasive ipsilateral breast recurrence in patients with good-risk ductal carcinoma in situ.

Real-World OS Outcomes Are Similar for Frontline CDK4/6 Inhibitor Combos in HR+, HER2– Breast Cancer

Real-World OS Outcomes Are Similar for Frontline CDK4/6 Inhibitor Combos in HR+, HER2– Breast Cancer

December 12th 2024

Retrospective data showed there was no OS difference between 3 frontline CDK4/6 inhibitor combos in HR-positive breast cancer.

Ribociclib and Endocrine Therapy in Breast Cancer | Image Credit: © Axel Kock – stock.adobe.com

Certain Breast Cancer Subtypes May Derive a Greater Benefit With Ribociclib Combo vs Chemo

December 12th 2024

Patients with luminal B and HER2E breast cancer subtypes may have a greater PFS benefit with ribociclib plus endocrine therapy vs combination chemotherapy.

ASH Annual Meeting | Image credit:  © Nittaya – stock.adobe.com

Optimizing Treatment Sequences Remains Key in CLL/SLL

December 12th 2024

Real-world data presented at the 2024 ASH Annual Meeting evaluated the efficacy of the most common treatment sequences in CLL/SLL.

ASH Annual Meeting | Image Credit: © Tatiana Shepeleva – stock.adobe.com

Iopofosine I 131 Is Efficacious, Tolerable in Heavily Pretreated R/R Waldenström Macroglobulinemia

December 12th 2024

Iopofosine I 131 demonstrated durable efficacy and tolerability in heavily pretreated relapsed/refractory Waldenström macroglobulinemia.

Azka Ali, MD, medical oncologist, Cleveland Clinic Taussig Cancer Institute

Dr Ali on the S0221 Trial of Alternative Chemo Dosing Schedules in Breast Cancer

December 12th 2024

Azka Ali, MD, discusses findings from the S0221 trial of alternative adjuvant anthracycline and taxane dosing schedules in high-risk, early breast cancer.

Ponatinib Risk Management in CML/ALL | Image Credit: © ivlianna stock.adobe.com

Risk Management Measures Improved Safety, Prevention, and Management of Ponatinib-Associated AEs in CML and AML

December 11th 2024

Select safety measures have improved the prevention and management of risks associated with ponatinib in ALL and CML over 10 years.

Breast cancer | Image Credit: © Sebastian Kaulitzki – stock.adobe.com

Imlunestrant With or Without Abemaciclib Boosts PFS in ESR1+, ER+/HER2– Advanced Breast Cancer

December 11th 2024

Imlunestrant with or without abemaciclib improved PFS in select patients with ER-positive, HER2-negative advanced breast cancer after endocrine therapy.

Neoadjuvant Patritumab Deruxtecan ± Letrozole Shows Efficacy in High-Risk HR+/HER2– Breast Cancer

Neoadjuvant Patritumab Deruxtecan ± Letrozole Shows Efficacy in High-Risk HR+/HER2– Breast Cancer

December 11th 2024

Neoadjuvant patritumab deruxtecan with or without letrozole produced pathologic complete responses in high-risk, HR-positive/HER2-negative breast cancer.

HER2+ Breast Cancer | Image Credit:   © Sebastian Kaulitzki - stock.adobe.com

SHR-A1811 Shows Initial Antitumor Activity, Tolerability in HER2+ Breast Cancer

December 11th 2024

SHR-A1811 monotherapy demonstrated high clinical activity and was well tolerated in patients with HER2-positive breast cancer.

Breast cancer | Image Credit:  © Sebastian Kaulitzki - stock.adobe.com

Adjuvant Olaparib Maintains iDFS Benefit in BRCA1/2+, HER2– Breast Cancer

December 11th 2024

Adjuvant olaparib maintained an efficacy benefit vs placebo in patients with BRCA1/2 mutation–positive, HER2-negative high-risk breast cancer.

Breast Cancer | Image Credit: © Axel Kock – stock.adobe.com

Elacestrant Plus Abemaciclib Shows Efficacy in ER+/HER2– Advanced or Metastatic Breast Cancer

December 11th 2024

Elacestrant plus abemaciclib demonstrated clinically important efficacy in ER-positive/HER2-negative advanced or metastatic breast cancer.

Hope S. Rugo, MD, FASCO, Winterhof Family Endowed Professor in Breast Cancer, professor, Department of Medicine (Hematology/Oncology), director, Breast Oncology and Clinical Trials Education; medical director, Cancer Infusion Services; the University of California San Francisco Helen Diller Family Comprehensive Cancer Center

Dr Rugo on Elacestrant-Based Combinations in ER+/HER2– Metastatic Breast Cancer

December 11th 2024

Hope S. Rugo, MD, FASCO, discusses updated safety findings from the ELEVATE trial of elacestrant-based combinations in ER+/HER2– metastatic breast cancer.

Smoldering Myeloma

Cilta-Cel Leads to 100% MRD-Negativity Rate in High-Risk Smoldering Multiple Myeloma

December 11th 2024

Cilta-cel without induction therapy in high-risk smoldering myeloma marked the first study of CAR T-cell therapy in a precursor cancer setting.

Risk-Reducing Surgery Improves Survival Outcomes in Younger BRCA+ Breast Cancer

Risk-Reducing Surgery Improves Survival Outcomes in Younger BRCA+ Breast Cancer

December 11th 2024

Risk-reducing surgery improved survival outcomes in younger patients with breast cancer and a germline BRCA mutation.

Breast Cancer | Image Credit: © Axel Kock – stock.adobe.com

Elacestrant Shows Tolerability in Combination With CDK4/6, PI3K Inhibitors in Advanced ER+ Breast Cancer

December 11th 2024

Elacestrant was partnered with multiple targeted agents across varying dose levels and schedules for patients with estrogen receptor–positive advanced breast cancer.

Virginia Kaklamani, MD, DSc, professor, medicine, Division of Hematology-Medical Oncology, The University of Texas (UT) Health Science Center San Antonio; leader, breast cancer program, Mays Cancer Center, UT Health San Antonio MD Anderson Cancer Center

Dr Kaklamani on the Effects of VAF on Elacestrant Outcomes in ER+ Breast Cancer

December 11th 2024

Virginia Kaklamani, MD, DSc, discusses an analysis of ESR1 allelic frequencies in elacestrant-exposed ER+/HER2– metastatic ESR1-mutated breast cancer.